DNA Polymerase Market

Market Overview

The global DNA polymerase market size was valued at USD 0.141 billion in 2022. It is projected to reach USD 0.180 billion by 2031, growing at a CAGR of 2.50% during the forecast period (2023-2031).

Highlights

• Prokaryotic DNA Polymerase dominates the type segment.
• DNA Cloning dominates the application segment.
• Diagnostic centers dominate the end-user segment.
• North America is the most significant shareholder in the global market.

DNA synthesis is accelerated during replication by a group of enzymes known as DNA polymerase. It duplicates a cell's DNA during cell division. Nucleotides are incorporated into the 3'OH group to digest the lengthening DNA strand. It is important because it makes it easier for genetic material to be passed from one generation to the next. The growing demand for PCR and DNA sequencing technologies in research and clinical applications drives the market. As genetic research advances and the need for personalized medicine grows, it is projected that the demand for DNA polymerases will rise even further.

New gene editing methods like CRISPR-Cas9 have contributed to the growth of the DNA polymerase market. DNA polymerase is crucial for DNA repair after Cas9 has cut the DNA, despite not being used directly in CRISPR-Cas 9. DNA polymerase replicates the template DNA molecule during HDR (Homology Directed Repair), altering the DNA sequence precisely. In addition, DNA polymerases are used in various gene editing techniques to insert, delete, or change DNA sequences. DNA polymerase is essential for locating and amplifying target DNA sequences in molecular diagnostics. The need for DNA polymerase enzymes has also significantly increased due to the advancement of DNA sequencing technologies. Since DNA polymerases are required enzymes for DNA sequencing and amplification, they are essential in the biotechnology industry.

Market Dynamics

Global DNA Polymerase Market Drivers:

Increasing Incidence of Chronic Diseases

A growing number of chronic diseases, such as cancer and cardiovascular disease, are being diagnosed and treated, which increases the demand for diagnostic and therapeutic technology. The demand for DNA polymerase has increased post Covid because PCR is used to amplify and largely relies on DNA polymerases. The usage of high-fidelity DNA polymerases in cancer treatment has increased recently. This increases the need for a high-quality DNA polymerase that can reliably copy DNA and detect mutations with high sensitivity and specificity. This also led to the creation of novel DNA polymerase products with improved fidelity, speed, and performance and specialized polymerases that can amplify and detect DNA sequences connected to illnesses.

Rising Strategic Initiatives and Growing Demand for Personalized Medicine

The demand for personalized care and cloning techniques is anticipated to rise over the forecast period. For instance, in November 2021, Genes2Me's launched its molecular product range, which includes next-generation technology, enzyme technology, cloning, and other product categories. The product range features the Fantom High-Fidelity DNA polymerase, which can enhance the sensitivity of PCR tests, making it an essential component of cloning technology. Therefore, the desire for personalized treatment is anticipated to expand, leading to further DNA polymerase use.

Additionally, strategic initiatives adopted by leading market participants are anticipated to accelerate market expansion over the forecast period. For instance, Ampliqon A/S debuted their AQ97 High-Fidelity DNA Polymerase in June 2021. The result delivers an enzyme with excellent fidelity, 60 times more fidelity than Taq polymerases, a high elongation rate of 10 seconds/kb, and a long-range capacity of 18 kb. Such product launches may have a favorable impact on market expansion in the ensuing years.

Global DNA Polymerase Market Restraint:

Rising Price of DNA Polymerase

The expansion of the DNA polymerase market is hampered by the increasing cost of enzymes used in DNA polymerases, which prevents the widespread adoption of emerging technologies that rely on them. DNA polymerases can be costly, meaning not all labs and hospitals can access them. In addition, biotechnology breakthroughs substantially impact the DNA polymerase industry by significantly increasing DNA polymerase pricing. It is also anticipated that the market for high-fidelity DNA polymerase will have slow growth due to a lack of knowledge in some research institutes and a lack of government financing in some developing nations.

Global DNA Polymerase Market Opportunities:

Substantial Use of DNA Polymerase in the Biotechnology Industries

DNA sequencing requires the use of DNA polymerase. DNA polymerase incorporates labeled nucleotides into the newly created DNA strand during sequencing. This approach is used to study and comprehend the human genome. The widely used PCR method of amplifying DNA sequences requires DNA polymerase. It is the enzyme responsible for extending the PCR primers, which are utilized to synthesize new DNA strands from a template DNA molecule.

In addition, modifying DNA molecules is utilized in genetic engineering to alter or add new genes. DNA polymerases are commonly used in biotechnology procedures, including gene therapy, protein expression, and recombinant DNA technology. Due to the biotechnology industry's expansion, the DNA polymerase market is expanding.

Regional Analysis

Based on region, the global DNA polymerases market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

North America Dominates the Global Market

North America dominates the market with a 47.28% share, which may be ascribed to the significant demand for biotechnology methods. Numerous well-known biotech and pharmaceutical companies with significant investments in developing novel medications and treatments are present in the region. The need for DNA polymerases is fueled by these businesses' use of DNA polymerases in PCR, sequencing, and genetic engineering. For instance, Cepheid introduced the Xpert Xpress MVP in November 2022. This multiplexed PCR assay can find DNA from organisms connected to bacterial trichomoniasis, vaginosis, and vulvovaginal candidiasis using a single sample. In addition, the prevalence of chronic diseases such as cancer, diabetes, and others has increased the need for DNA polymerase in biotechnology labs for DNA replication and later extension. For instance, the WHO estimates that 37.3 million Americans have diabetes, 96 million US adults have prediabetes, and the estimated annual cost of diabetes is USD 327 billion; the market for DNA polymerase will grow as recombinant medications for treating chronic diseases become more common.

Asia-Pacific is expected to grow at the fastest CAGR of 2.07% during the forecast period. The high prevalence of the target disorders, rising funding for genomic research, and growing understanding of genetic testing in the region can all be credited for this growth. Domestic and foreign market participants are making significant investments in creating innovative DNA polymerases, which are anticipated to boost the region's growth in the ensuing years.

Segmental Analysis

The global DNA polymerase industry is segmented into type, application, and end user.

Based on the type, the global market is bifurcated into Prokaryotic DNA Polymerase and Eukaryotic DNA Polymerase.

The prokaryotic DNA polymerase segment owns the highest market share due to its use in diagnostic procedures like PCR testing. Due to recent significant investments in genome research and potential uses outside the scope of conventional medical applications, eukaryotic DNA polymerase is also expected to experience rapid development. In addition, high-fidelity DNA polymerase will be introduced, which will benefit the expansion process.

Based on the application, the global market is split into DNA cloning, SNP analysis, next-generation sequencing applications, and other applications.

The DNA cloning segment is the highest contributor to the market and is expected to grow at a CAGR of 1.88% during the forecast period. Making numerous, exact copies of a specific segment of DNA is known as DNA cloning. Researchers create copies of the genes they want to examine using the gene cloning procedure. Numerous industries use DNA cloning, such as medicine, agriculture, and fundamental biological research. DNA cloning is employed in medicine to create huge numbers of proteins that can be turned into medications to cure illnesses. Agriculture also employs cloning to create duplicates of animals with desired characteristics, such as high milk production or lean meat.

Based on end-user, the global market is categorized into pharmaceutical and biotechnology companies, academic and research institutes, diagnostic centers, and others.

The diagnosis segment owns the highest market share and is expected to grow at a CAGR of 1.97% over the forecast period. Diagnostic centers held the largest market share of 39.05% in 2022 due to the increasing prevalence of genetic abnormalities and infectious diseases like COVID-19, which increased their use of PCR testing for diagnosis. For instance, COVID-19 PCR tests were performed at more than 1,000 laboratories in the United States in 2020, including hospitals and diagnostic centers. Therefore, the overwhelming share of the category in 2022 was primarily driven by the rising demand for PCR testing and the use of polymerases for various diagnostic applications.

The academic and research institutes segment is expected to experience the fastest CAGR during the forecast period due to increased funding and investment programs from government agencies and commercial organizations. These initiatives seek to promote this field's research. For instance, the University of California, Irvine, was awarded a USD 2.5 million grant by the John and Mary Tu Foundation in May 2020 to carry out studies, tests, and discoveries that would improve the care of COVID-19 patients. Such investment supports the creation of new technologies and is anticipated to drive the segment's expansion.

Recent Developments

• April 2023- Agilent Technologies Inc. announced the launch of the Agilent Cancer Assay. This assay was developed in partnership with important cancer researchers for distinct somatic profiling for solid tumor types on a larger scale.

• April 2023- Takara Bio Inc. announced that it had submitted a clinical trial application to Health Canada and had heard nothing to stop it from starting a trial for CD19 treatment. Once the operation is finished, the clinical trial will begin for patients who test CD19-positive.

• September 2022- Oxidative damages were produced and repaired in "junk" DNA, according to research from the Healthy Life Span Institutes and the University of Sheffield's Neuroscience Department published. The discoveries open the door to the creation of cancer medications and cures for neurological diseases, including Alzheimer's and dementia.